Gepotidacin

Unassigned

New Medicines

Complicated urinary tract infection

Information

New molecular entity
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Triazaacenaphthylene bacterial topoisomerase inhibitors (Type II DNA topoisomerase inhibitor). New mode of action.
UTIs are among the most common bacterial infections encountered in the community. Up to 10% of women have a urinary tract infection in a given year and 50% of all women experience at least one UTI at some point in their lives [1].
Complicated urinary tract infection
Intravenous and
Oral

Urogenital gonorrhoea

Information

New molecular entity
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Triazaacenaphthylene bacterial topoisomerase inhibitors (Type II DNA topoisomerase inhibitor). New mode of action.
There were 56,259 diagnoses of gonorrhoea reported in 2018, a 26% increase since 2017.[1]
Urogenital gonorrhoea
Intravenous and
Oral